Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Roberto Butera"'
Autor:
Shabnam Shaabani, Louis Gadina, Ewa Surmiak, Zefeng Wang, Bidong Zhang, Roberto Butera, Tryfon Zarganes-Tzitzikas, Ismael Rodriguez, Justyna Kocik-Krol, Katarzyna Magiera-Mularz, Lukasz Skalniak, Alexander Dömling, Tad A. Holak
Publikováno v:
Molecules, Vol 27, Iss 11, p 3454 (2022)
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the compounds displayed exc
Externí odkaz:
https://doaj.org/article/67a2552841844f3d9aa8c069ce56167b
Autor:
Katarzyna Guzik, Marcin Tomala, Damian Muszak, Magdalena Konieczny, Aleksandra Hec, Urszula Błaszkiewicz, Marcin Pustuła, Roberto Butera, Alexander Dömling, Tad A. Holak
Publikováno v:
Molecules, Vol 24, Iss 11, p 2071 (2019)
Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such
Externí odkaz:
https://doaj.org/article/f8845f78c3864840bfe4b4868e458431
Autor:
Constantinos G. Neochoritis, Zlata Boiarska, Roberto Butera, Markella Konstantinidou, Justyna Kalinowska-Tluscik, Alexander Doemling, Katarzyna Kurpiewska
Publikováno v:
European Journal of Organic Chemistry, 2020(34), 5601-5605. WILEY-V C H VERLAG GMBH
Imidazopyrimidines with diverse substitution patterns are a prime class of heterocycles, present in many commercially available or late-stage clinical trials drugs. Here, we describe a fast access to diaminoimidazopyrimidines by means of a powerful m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422aa079dab897c03fb60547a9442519
https://hdl.handle.net/11370/97bd2aed-0241-4934-8715-7b346cf5bb03
https://hdl.handle.net/11370/97bd2aed-0241-4934-8715-7b346cf5bb03
Autor:
Roberto Butera, Annadka Shrinidhi, Alexander Dömling, Justyna Kalinowska-Tłuścik, Katarzyna Kurpiewska
Publikováno v:
Chemical communications (Cambridge, England), 56(73), 10662-10665. ROYAL SOC CHEMISTRY
Oligoisocyanides are attractive synthetic targets, however, only a few are known. Here, we describe the smallest stable tetraisocyanide possible, the 1,3-diisocyano-2,2-bis(isocyano-methyl)propane (1) with S4 symmetry. Its four-step synthesis, struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b078597795ef364f2e0d6252e272f8f
https://doi.org/10.1039/d0cc04522e
https://doi.org/10.1039/d0cc04522e
Autor:
Markella Konstantinidou, Kumchok C Mgimpatsang, Svitlana V. Shishkina, Roberto Butera, Alexander Dömling, Qian Wang, Angelina Osipyan
Publikováno v:
The Journal of Organic Chemistry
The Journal of Organic Chemistry, 84(18), 12148-12156. AMER CHEMICAL SOC INC
The Journal of Organic Chemistry, 84(18), 12148-12156. AMER CHEMICAL SOC INC
Here we describe a facile, tandem synthetic route for indolo[3,2-c]quinolinones, a class of natural alkaloid analogues of high biological significance. A Ugi four-component reaction with indole-2-carboxylic acid and an aniline followed by a Pd-cataly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a4b5afa12412dbef569c733e08f0f84
https://doi.org/10.1021/acs.joc.9b01258
https://doi.org/10.1021/acs.joc.9b01258
Autor:
M. Wazynska, Dominik Sala, Alexander Dömling, Philip H. Elsinga, Radoslaw Kitel, Hans W. Nijman, Tad A. Holak, Marco de Bruyn, Bogdan Musielak, Roberto Butera, Ewa Surmiak, Jacek Plewka, Katarzyna Magiera-Mularz
Publikováno v:
Bioorganic & Medicinal Chemistry Letters, 12(5), 768-773. American Chemical Society
ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters
The PD-1/PD-L1 axis has proven to be a highly efficacious target for cancer immune checkpoint therapy with several approved antibodies. Also, small molecules based on a biphenyl core can antagonize PD-1/PD-L1, leading to the in vitro formation of PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae8b3d842371e8c0db6d401b24a307a
https://ruj.uj.edu.pl/xmlui/handle/item/278603
https://ruj.uj.edu.pl/xmlui/handle/item/278603
Autor:
Roberto, Butera, Annadka, Shrinidhi, Katarzyna, Kurpiewska, Justyna, Kalinowska-Tłuścik, Alexander, Dömling
Publikováno v:
Chemical communications (Cambridge, England). 56(73)
Oligoisocyanides are attractive synthetic targets, however, only a few are known. Here, we describe the smallest stable tetraisocyanide possible, the 1,3-diisocyano-2,2-bis(isocyano-methyl)propane (1) with S4 symmetry. Its four-step synthesis, struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::32fe3236c8be41d1c560ead5bc098012
https://pubmed.ncbi.nlm.nih.gov/32785316
https://pubmed.ncbi.nlm.nih.gov/32785316
Autor:
Katarzyna Magiera-Mularz, Alexander Dömling, Ariana Kouchi, Harmen P.S. Huizinga, Katarzyna Guzik, Shabnam Shaabani, Roberto Butera, Tad A. Holak
Publikováno v:
Expert Opinion on Therapeutic Patents, 28(9), 665-678. Taylor & Francis Ltd
Introduction: The protein-protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761927e2286405043c7b717046d225b1
https://research.rug.nl/en/publications/f43a53f5-55c2-4bf4-abac-ad6d4d4591e2
https://research.rug.nl/en/publications/f43a53f5-55c2-4bf4-abac-ad6d4d4591e2
Autor:
Roberto Butera, Alexander Dömling, Marcin Tomala, Marcin Pustula, Urszula Błaszkiewicz, Tad A. Holak, Aleksandra Hec, Magdalena Konieczny, Katarzyna Guzik, Damian Muszak
Publikováno v:
Molecules
Molecules, Vol 24, Iss 11, p 2071 (2019)
Molecules, Vol 24, Iss 11, p 2071 (2019)
Cancer immunotherapy based on antibodies targeting the immune checkpoint PD-1/PD-L1 pathway has seen unprecedented clinical responses and constitutes the new paradigm in cancer therapy. The antibody-based immunotherapies have several limitations such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b208c73e1d9b9b5409e787c235de2fd7
https://doi.org/10.3390/molecules24112071
https://doi.org/10.3390/molecules24112071